A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome

Thyroid

Volumn 19, Issue 3, 2009, Pages 233-240

  Mooney, Colin J ^a   Nagaiah, Govardhanan ^a   Fu, Pingfu ^a,b   Wasman, Jay K ^b   Cooney, Matthew M ^a,b   Savvides, Panos S ^a,b   Bokar, Joseph A ^a,b   Dowlati, Afshin ^a,b   Wang, Ding ^c   Agarwala, Sanjiv S ^d,f   Flick, Susan M ^a   Hartman, Paul H ^a   Ortiz, Jose D ^a,b   Lavertu, Pierre N ^a,b   Remick, Scot C ^a,b,e  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KARMANOS CANCER INSTITUTE   (United States)

^d ST LUKE S HOSPITAL   (United States)

^e WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; DOXORUBICIN; FOSBRETABULIN; INTERCELLULAR ADHESION MOLECULE 1; PACLITAXEL; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ADULT; ADVANCED CANCER; AGED; ANAPLASTIC CARCINOMA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD LEVEL; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIAPHORESIS; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLUSHING; HEADACHE; HEART ARRHYTHMIA; HUMAN; KAPLAN MEIER METHOD; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NAUSEA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; QT PROLONGATION; SIDE EFFECT; SINUS TACHYCARDIA; SURVIVAL TIME; THYROID CARCINOMA; VOICE CHANGE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIBENZYLS; CARBOPLATIN; CARCINOMA; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEURAL CELL ADHESION MOLECULES; ORGANOPHOSPHORUS COMPOUNDS; PACLITAXEL; SURVIVORS; THYROID NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 62349137638     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2008.0321     Document Type: Article

References (47)

1. Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A 2005 Anaplastic thyroid carcinoma treatment outcome and prognostic factors. Cancer 103:1330-1335.
2. McIver B, Hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson, GB, van Heerden JA, Goellner JR 2001 Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 130:1028-1034.
3. Albores-Saavedra J, Henson DE, Glazer E, Schwartz AM 2007 Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype - papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocr Pathol 18:1-7.
4. Are C, Shaha AR 2006 Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 13:453-464.
5. Hundahl SA, Fleming ID, Fremgen AM, Menck HR 1998 A National Cancer Center Data Base report on 53,856 cases of thyroid carcinoma treated in the US, 1985-1995. Cancer 83:2638-2648.
6. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ 2007 Cancer statistics, 2007. CA Cancer J Clin 57:43-66.
7. Fagin JA 1994 Molecular genetics of human thyroid neoplasms. Annu Rev Med 45:45-52.
8. Gilliland FD, Hunt WC, Morris DM, Key CR 1997 Prognostic factors for thyroid carcinoma. A population based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-91. Cancer 79:564-573.
9. Lehnert M 1996 Clinical multidrug resistance in cancer: a multifactorial problem. Eur J Cancer 32:912-920.
10. Satake S, Sugawara I, Watanabe M, Takami H 1997 Lack of point mutation of human DNA topoisomerase II in multidrug-resistant anaplastic thyroid carcinoma cell lines. Cancer 116:33-39.
11. Ahuja S, Ernst H 1987 Chemotherapy of thyroid carcinoma. J Endocrinol Invest 10:303-310.
12. Ain KB, Egorin MJ, DeSimone PA for the Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group 2000 Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-sixhour infusion. Thyroid 10:587-594.
13. Gottlieb JA, Hill CS Jr. 1974 Chemotherapy of thyroid cancer with Adriamycin. N Engl J Med 290:193-197.
14. Young SL, Chaplin DJ 2004 Combretastatin A4 phosphate: background and current clinical status. Expert Opin Investig Drugs 13:1171-1182.
15. Chaplin DJ, Pettit GR, Hill SA 1999 Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 19:189-195.
16. Grosios K, Holwell SE, McGown AT, Pettit GR, Bibby MC 1999 In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 81:1318-1327.
17. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, Taylor A, Waas J, Lewin JS, McCrae KR, Remick SC 2002 A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62:3408-3416.
18. Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, Gumbrell L, Price PM 2003 Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 21:2815-2822.
19. Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, Giantonio B, Zimmer R, Petros WP, Stratford M, Chaplin D, Young SL, Schnall M, O'Dwyer PJ 2003 Phase I trial of the antivascular agent combretastatin A-4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 21:4428-4438.
20. Akerley WL, Schabel M, Morrell G, Horvath E, Yu M, Johnsson B, Arbogast K 2007 A randomized phase 2 trial of combretatstatin A-4 phosphate (CA4P) in combination with paclitaxel and carboplatin to evaluate safety and efficacy in subjects with advanced imageable malignancies. J Clin Oncol 2007 ASCO Ann Meeting Proc 25:616s (Abstract no. 14060).
21. Bilenker JH, Flaherty KT, Rosen M, Davis L, Gallagher M, Stevenson JP, Sun W, Vaughn D, Giantonio B, Zimmer R, Schnall M, O'Dwyer PJ 2005 Phase I trial of combretastatin A-4 phosphate with carboplatin. Clin Cancer Res 11:1527-1533.
22. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ 1997 Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57:1829-1834.
23. Dorr RT, Dvorakova K, Snead K, Alberts DS, Salmon SE, Pettit GR 1996 Antitumor activity of combretastatin-A4 phosphate, a natural product tubulin inhibitor. Investig New Drugs 14:131-137.
24. el-Zayat AA, Degen D, Drabek S, Clark GM, Pettit GR, Von Hoff DD 1993 In vitro evaluation of the antineoplastic activity of combretastatin A-4, a natural product from Combretum caffrum (arid shrub). Anticancer Drugs 4:19-25.
25. Griggs J, Metcalfe JC, Hesketh R 2001 Targeting tumour vasculature: the development of combretastatin A4. Lancet Oncol 2:82-87.
26. Grosios K, Loadman PM, Swaine DJ, Pettit GR, Bibby MC 2000 Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res 20:229-233.
27. Landuyt W, Verdoes O, Darius DO, Drijkoningen M, Nuyts S, Theys J, Stockx L, Wynendaele W, Fowler JF, Maleux G, van den Bogaert W, Anne J, van Oosterom A, Lambin P 2000 Vascular targeting of solidtumours: a major "inverse" volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas. Eur J Cancer 36:1833-1843.
28. Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, Dennis MF, Chaplin DJ 1999 Combretastatin A-4 phosphate as a tumor vascular targeting agent: early effects in tumors and normal tissues. Cancer Res 59:1626-1634.
29. Vincent L, Kermani P, Young LM, Cheng J, Zhang F, Shido K, Lam G, Bompais-Vincent H, Zhu Z, Hicklin DJ, Bohlen P, Chaplin DJ, May C, Rafii S 2005 Combretastatin A-4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest 115:2992-3006.
30. Yeung SC, She M, Yang H, Pan J, Sun L, Chaplin D 2007 Combination chemotherapy including combretastatin A-4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model. J Clin Endocrinol Metab 92:2902-2909.
31. National Cancer Institute Common Toxicity Criteria (CTC), Version 2.0 1998 National Cancer Institute, Bethesda, MD.
32. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0 2006 National Cancer Institute, Bethesda, MD.
33. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG 2000 New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216.
34. Kaplan EL, Meier P 1958 Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481.
35. de Crevoisier R, Baudin E, Bachelot A, Leboulleux S, Travagli J-P, Caillou B, Schlumberger M 2004 Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys 60:1137-1143.
36. Cooney M, Radivoyevitch T, Dowlati A, Overmoyer B, Levitan N, Robertson K, Levine SL, DeCaro K, Butcher C, Taylor A, Stambler BS, Remick SC 2004 Cardiovascular safety-profile of combretastatin A4 phosphate (CA4P) in a single-dose phase I pharmacokinetic study in patients with advanced cancer. Clin Cancer Res 10:96-100.
37. van Heeckeren WJ, Bhakta S, Ortiz J, Duerk J, Cooney MM, Dowlati A, McCrae K, Remick SC 2006 Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists? J Clin Oncol 24:1485-1488.
38. van Heeckeren WJ, Sanborn SL, Narayan A, Cooney MM, McCrae KR, Schmaier AH, Remick SC 2007 Complications from vascular-disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis. Curr Opin Hematol 14:468-480.
39. Ke Q, Bodyak N, Rigor D, Kang P 2007 Exaggerated hypertensive response of combretastatin A-4 phosphate in hypertensive rats. International Conference of Vascular Targeted Therapies Oncology, Mandelieu, Cannes, France (Abstract no. 25).
40. Rustin GJ, Nathan PD, Boxall J, Saunders L, Ganesan TS, Shreeves GE 2005 A phase Ib trial of combretastatin A-4 phosphate (CA4P) in combination with carboplatin or paclitaxel chemotherapy in patients with advanced cancer. J Clin Oncol ASCO Ann Meeting Proc 23:217s (Abstract no. 3103).
41. Cooney MM, Tserng KY, Makar V, McPeak RJ, Ingalls ST, Dowlati A, Overmoyer B, McCrae K, Ksenich P, Laavertu P, Ivy P, Hoppel CL, Remick S 2005 A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck. Cancer Chemother Pharmacol 55:295-300.
42. Dowlati A, Robertson K, Radivoyevitch T, Waas J, Ziats, NP, Hartman P, Abdul-Karim FW, Wasman JK, Jesberger J, Lewin J, McCrae K, Ivy P, Remick SC 2005 Novel phase I dose de-escalation design trial to determine the biological modulatory dose of the anti-angiogenic agent SU5416. Clin Cancer Res 11:7938-7944.
43. Overmoyer B, Fu P, Hoppel C, Radivoyevitch T, Shenk R, Persons M, Silverman P, Robertson K, Ziats NP, Wasman JK, Abdul-Karim FW, Jesberger JA, Duerk J, Hartman P, Hanks S, Lewin J, Dowlati A, McCrae K, Ivy P, Remick SC 2007 Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin. Clin Cancer Res 13:5862-5868.
44. Lyons JA, Silverman P, Remick S, Chen H, Leeming R, Shenk R, Fu P, Dumadag L, Escuro K, Overmoyer B 2006 Toxicity results and early outcome data on a randomized phase II study of docetaxel ± bevacizumab for locally advanced, unresectable breast cancer. J Clin Oncol 6 ASCO Ann Meeting Proc 24:133s (Abstract no. 3049).
45. Baar J, Silverman P, Lyons J, Fu P, Abdul-Karim F, Ziats N, Wasman J, Hartman P, Jesberger J, Dumadag L, Hohler E, Leeming R, Shenk R, Chen H, McCrae K, Dowlati A, Remick S, Overmoyer B 2009 A vasculature-targeting regimen of pre-operative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers. Clin Cancer Res (In press).
46. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 355:2542-2550.
47. Dowlati A, Gray R, Sandler AB, Schiller JH, Johnson DH 2008 Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab - an Eastern Cooperative Group study. Clin Cancer Res 14:1407-1412.